Shots:

• Redx to receive $10M as up front followed by another $10M in year two and will receive up to $400M as milestones along with royalties on sales of the therapies. The first milestone is payable following IND submission
• Following a successful IND submission- Jazz will be responsible for further development- manufacturing- regulatory activities- and commercialization. The two companies will discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway
• The collaboration follows sale of Redx's pre-clinical pan-RAF inhibitor program to Jazz for the treatment of Raf and Ras mutant tumors in July’2019

­ Ref: Jazz Pharmaceutical  | Image: Getty Images